Aspirin Use and Risk of Colorectal Cancer According to BRAF Mutation Status | Zendy

Reiko Nishihara | Zendy; Paul Lochhead | Zendy; Aya Kuchiba | Zendy; Seungyoun Jung | Zendy; Mai Yamauchi | Zendy; Xiaoyun Liao | Zendy; Yu Imamura | Zendy; Zhi Rong Qian | Zendy; Teppei Morikawa | Zendy; Molin Wang | Zendy; Donna Spiegelman | Zendy; Eunyoung Cho | Zendy; Edward L. Giovannucci | Zendy; Charles S. Fuchs | Zendy; Andrew T. Chan | Zendy; Shuji Ogino | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Aspirin Use and Risk of Colorectal Cancer According to BRAF Mutation Status

Author(s) -

Reiko Nishihara,

Paul Lochhead,

Aya Kuchiba,

Seungyoun Jung,

Mai Yamauchi,

Xiaoyun Liao,

Yu Imamura,

Zhi Rong Qian,

Teppei Morikawa,

Molin Wang,

Donna Spiegelman,

Eunyoung Cho,

Edward L. Giovannucci,

Charles S. Fuchs,

Andrew T. Chan,

Shuji Ogino

Publication year - 2013

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2013.6599

Subject(s) - medicine , aspirin , colorectal cancer , cancer , incidence (geometry) , oncology , kras , hazard ratio , proportional hazards model , gastroenterology , confidence interval , physics , optics

Aspirin use reduces the risk of colorectal carcinoma. Experimental evidence implicates a role of RAF kinases in up-regulation of prostaglandin-endoperoxide synthase 2 (PTGS2, cyclooxygenase 2), suggesting that BRAF-mutant colonic cells might be less sensitive to the antitumor effects of aspirin than BRAF-wild-type neoplastic cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research